Tonabersat (also known as SB-220453), a benzopyran derivative, is a novel and potent gap-junction modulator used for the prevention of migraine.

AT-1001, formerly known as Larazotide Acetate, is a novel and synthetic peptide acting as a tight junction regulator and reverses leaky junctions to their normally closed state. It is being studied in people with celiac disease.

Danegaptide hydrochloride (GAP-134 and ZP-1609) is a novel, potent, selective and orally bioavailable small molecule gap-junction modifier with a potential for the treatment of atrial fibrillation.

Gap 26 is a novel and potent connexin mimetic peptide.

Gap 27 is a connexin43 peptide derivative that acts as a novel and potent gap junction inhibitor.